Effect of Ginger on Inflammatory Diseases: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Pura Ballester
,
Begoña Cerdá
,
Raúl Arcusa
,
Javier Marhuenda
,
Karen Yamedjeu
,
Pilar Zafrilla

Ulcerative colitis, Crohn’s disease, rheumatoid arthritis, psoriasis, and lupus erythematosus are some of common inflammatory diseases. These affections are highly disabling and share signals such as inflammatory sequences and immune dysregulation. The use of foods with anti-inflammatory properties such as ginger (Zingiber officinale Roscoe) could improve the quality of life of these patients. Ginger is a plant widely used and known by its bioactive compounds. There is enough evidence to prove that ginger possesses multiple biological activities, especially antioxidant and anti-inflammatory capacities.

  • inflammatory diseases
  • ginger
  • bioactive compounds

1. Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by peripheral pain involving joints (hands, feet, wrists, shoulders, elbows, hips, and knees). It is characterized by a tight interaction between cells and mediators of the innate and adaptive immune system [1]. While the cause of RA is unknown, it is influenced by genetic, epigenetic, and environmental factors. Pain, swelling secondary to inflammation of the synovial membrane, and stiffness occur, especially in the morning or after prolonged periods of rest. In addition to damaging the joints and surrounding tissues (tendons and muscles) that can lead to decreased mobility and joint function, chronic inflammation can affect other organs, such as the heart, lung, or kidney [2]. In addition, if the inflammation is high and sustained, it can cause fever, fatigue, asthenia, weight loss, and loss of appetite. Therefore, rheumatoid arthritis is considered a systemic disease [3].
The pathophysiological mechanisms for RA are not fully elucidated; however, it is clear that the immune system is compromised, causing chronic inflammation, and there is also oxidative stress [4][5]. Actual treatment for RA consists of immunomodulation or immunosuppression and symptomatic treatment (anti-inflammatories), but this treatment does not cure the disease. Since the development of RA depends on environmental factors, including diet, it is logical to think that certain foods or nutrients with an anti-inflammatory and antioxidant character may be useful in this pathology [6].
In this sense, ginger is a very good candidate, as it has antioxidant and anti-inflammatory properties. In fact, since ancient times, ginger has been used in medicine as an anti-inflammatory. It is currently known that this is due to the fact that the bioactive compounds in ginger are capable of inhibiting the COX-2 and LOX pathway [7]. Both in vitro and in vivo models have proved that ginger has antiarthritic effects [7][8].
One of the most abundant bioactive compounds of ginger is 6-shogaol. In vitro and in vivo, 6-shogaol has been shown to exhibit cancer protective effects, anti-inflammatory, antioxidant, and neuroprotective actions [9]. In vivo, 6-shogaol successfully reduced the formation of paw edema [10], leukocyte infiltration into the tissue, or symptoms of arthritis [11][12][13]. Bashir et al. verified how zingerone is capable of improving inflammation and oxidative stress in an animal model of arthritis [14].

2. Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is an umbrella term for various chronic inflammatory digestive processes, the etiology of which is unknown. Crohn’s disease and ulcerative colitis are among these processes. Crohn’s disease can be located anywhere in the gastrointestinal tract, from the mouth to the anus, although it usually occurs in the distal ileum and ascending colon. Ulcerative colitis is mainly located in the rectum and distal colon, although it may extend to the entire colon. The inflammatory process is discontinuous and asymmetrical. Unlike Crohn’s disease, ulcerative colitis starts in the rectum, where it gives rise to the so-called ulcerative proctitis [15]. The most common clinical symptoms of ulcerative colitis include abdominal pain, diarrhea, and bloody mucoid stools.
In relation to the pathogenesis of the disease, it is recognized that in addition to genetic factors, there are additional triggering factors, so-called environmental precipitants, and disease cofactors. In this sense, a precipitating factor would be an infection by a certain pathogen, coupled with a defective function of the intestinal barrier, which would trigger a chronic inflammatory response in genetically predisposed individuals with impaired regulation of the immune system.
The immune response of the gastrointestinal tract can lead to inflammation when the immune system and commensal bacteria balance is altered. This alteration occurs more frequently in genetically predisposed individuals. The gut microbiome plays an important role in the treatment of IBD [16]. For the already reported dysbiosis in patients with ulcerative colitis and Crohn’s disease compared to controls, Guo et al. [17] showed that ginger can improve the functions of the gut microbiota, restoring its diversity. Patients with Crohn’s disease and ulcerative colitis have an increased proportion of Proteobacteria and a decreased proportion of Firmicutes [18].
In gut homeostasis, Toll-like receptors (TLRs) play a pivotal role as mediators between the gut microbiome and the immune response. Pathogen-associated molecular patterns (PAMPs) are recognized by TLRs and upon recognition are activated, regulating dendritic cell maturation, adaptive immunity, and innate immunity. Expression of TLRs increases when these regulations are altered, leading to an increase in inflammatory cytokines and an increased risk of inflammatory bowel diseases [19]. TLR4 signaling is involved in inflammatory bowel disease and drug treatment efficacy [20].
Pharmacological treatment of IBD is based on non-specific anti-inflammatory and immunosuppressive drugs with suboptimal results. The goal of IBD therapy is to induce and maintain remission and ameliorate the disease’s secondary effects [21]. In addition to pharmacological treatment, diet plays a key role [22].
There are bioactive substances from different foods that can be used in the prevention and treatment of inflammatory bowel diseases. Among these substances is glycomacropeptide (GMP), a peptide derived from milk K-casein with immunomodulatory, bactericidal, and prebiotic effects. Curcumin is a yellow pigment from turmeric (Curcuma longa), a spice of Indian origin that has beneficial health effects. Curcumin ameliorates altered intestinal barrier function caused by inflammation by reducing myosin light chain kinase (MLCK) expression. It also decreases the production of TNF-α, IL-4, IL-6, and IL-13 by MCs in response to allergens [23].
There is a need to develop novel effective therapies and adjuvants for the treatment of IBD, as conventional treatment can have side effects (such as nausea, pancreatitis, allergic reactions) and is relatively often ineffective in some patients [24]. Ginger has antioxidant, antitumor, anti-inflammatory, and anti-ulcer effects, and has also been used for many years throughout the world to treat vomiting, diarrhea, and infections [25].
In IBD, ginger modulates the inflammatory response through suppression of nuclear factor kappa B (NF-κB), TNF-α, Nod-like receptor family proteins (NLRP), TLR, signal transducer of activators of transcription (STAT), mitogen-activated protein kinase (MAPK), and mTOR pathways, as well as inhibiting several proinflammatory cytokines (I L-6, IL-1β) and myeloperoxidase enzyme (MPO) [26][27].
Several authors have observed that gingerols and shogaols present in the rhizome decrease hepatic markers of inflammation by inhibiting NF-κB activity after consumption of a high-fat diet [28]. TNF-alpha inhibition leads to modulation of the inflammatory response, resulting in downregulation of the NF-κB signaling [29].
The oral consumption of gingerol, a bioactive substance in ginger, decreased the values of cytokines (IL-1beta, IL-6), TNF-alpha, NF-kB (p65), and increased IL-10 in an animal model of mice with ulcerative colitis induced by dextran sulfate sodium. Moreover, it decreased cyclooxygenase-2 (COX-2) enzyme activity and monocyte chemoattractant protein-1 (MCP-1) [26].
6-shogaol is a bioactive substance from dried ginger with anti-inflammatory properties. Several authors have observed that it increases the expression of the nuclear factor (erythroid-derived 2)-like 2 (Nrf-2) and heme oxygenase (HO-1) in DDS-induced colitis in a mouse model. It has also been shown to reduce the expression of IL-6, IL-1beta, and TNF-alpha [29][30]. However, the results are still scarce and in some cases contradictory, since in a pilot study of 45 patients with IBD, Van Tilburg et al. [31] observed that ginger did not have any beneficial effect when compared to a placebo group.

3. Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory connective tissue disease that affects the joints, kidneys, skin, mucous membranes, and blood vessel walls. SLE is characterized by overactivation of the autoimmune system with abnormal functions of innate and adaptive immune cells and the production of a large number of autoantibodies against nuclear components [32]. However, at the present time, there is no clear etiology for this inflammatory disease, although enough evidence is gathered about the implication of genetic and environmental factors. Additionally, a wide variety of clinical manifestations, comorbid conditions, and a complex pathogenesis coexist in SLE. According to the literature, for the disease to manifest, there must be (in addition to a genetic predisposition) different hormonal, nutritional, and environmental factors that contribute to its pathogenesis [33].
There are many immune cells and proinflammatory proteins that are part of the complex pathogenesis of lupus which could be therapeutic targets [34]. The pharmacological treatment of SLE is based on four main types of drugs: non-steroidal anti-inflammatory drugs, antimalarial drugs, anti-inflammatory corticosteroids, and biological therapies [35]. The right pharmacological treatment for SLE is still a matter of controversy, and multiple simultaneous approaches are currently being used. However, in recent years, diet, microbiota, stress, and physical activity are receiving more attention from researchers. Bearing in mind that in SLE there is a there is a dysfunction of the immune system and an exacerbated inflammatory response, those bioactive substances that improve immune function and reduce chronic inflammation could be useful in the treatment of this pathology. The bioactive compounds of ginger have been proved these actions. It is clear that ginger has a potent antioxidant and anti-inflammatory activity. Hence, the anti-inflammatory effects of ginger are yet to be further investigated in the context of SLE.

4. Psoriasis

Psoriasis is a chronic inflammatory skin condition marked by keratinocyte overgrowth and inflammation, which leads to epidermal hyperplasia, a characteristic of lesioned psoriatic skin. The elbows, knees, and scalp are the most common sites for psoriatic plaques. There is still no therapy for psoriasis, despite recent research revealing aspects of the pathogenesis and the extensive interplay involving nerves, immune system, endocrine system, and skin cells [36]. Oxidative stress is a key factor in the development and progression of psoriasis, which is known to be caused by a number of factors, including alcohol consumption, smoking, infection, drugs, obesity, cell metabolism, immune response, and pathological state [37]. The production of reactive oxygen species is a critical step in the creation of oxidative stress in psoriasis.
They generally act as second messengers during this process and lead to an increase in the levels of oxidative products which result in the activation of Th1 and Th17 cells and keratinocytes through the MAPK, NF-kβ, and JAK-STAT pathways. This results in a cascade of inflammatory cytokines and growth factors. NF-kβ is an essential inflammatory mediator in the pathogenesis of psoriasis; increased expression of NF- β has been demonstrated in psoriatic lesions [38]. The phosphorylation of the inhibitor of kappa B kinase (IKK) complex by ROS can activate NF-kβ [39]. H2O2, which is transported by AQP3, has been linked to the activation of the NF-kβ signaling pathway in keratinocytes and the pathogenesis of psoriasis [40]. Altered NF-kβ signaling disrupts the balance of apoptotic signals, leading to the upregulation of cyclins and survivins, thereby inhibiting apoptosis. Furthermore, NF-kβ stimulates the synthesis of IL-17 and TNF-, boosting the inflammatory response downstream [37]. Eukaryotic cells use the NF-kβ pathway as a regulator of genes that affect cell proliferation and survival. NF-kβ regulates the inflammatory response by increasing the expression of inflammatory target genes such as cytokines, chemokines, and COX2. This enzyme increases the production of proinflammatory cytokines by triggering the creation of certain prostaglandins in response to inflammation.
Ginger inhibits inflammatory responses by decreasing NF-kβ, which results in a decrease in cytokine gene expression [41]. Several authors [42] have observed that administration for 21 days of ginger and metformin in liposomes decreases TNF-α and IL-22 levels. These results show that ginger’s bioactive compounds could be an alternative treatment for psoriasis treatment.

5. Cancer

There is growing evidence linking diet to cancer prevention and treatment. Cancer is the second leading cause of death in the world after cardiovascular disease, with important socio-economic consequences. Certain dietary components, such as ginger and its compound 6-gingerol, may be associated with a reduced risk of cancer development [43]. Inflammatory processes are associated with tumor progression [44]. Several authors [45] described the anti-inflammatory action of ginger extract in vivo cancer models in animals significantly reduced the elevated expression of TNF-alpha and NF-kβ in rats with liver cancer.
De Lima et al. [46] showed that ginger derivatives, as an extract or isolated compounds, exhibit relevant antiproliferative effects on tumoral cells, as well as anti-inflammatory activities. 6-gingerol is the most pharmacologically active compound possessing potential cancer protection properties via its effect on a variety of biological pathways involved in apoptosis, inhibition of angiogenesis, cell cycle regulation, and cytotoxic activity. Ginger extract and 6-gingerol exert their action through important mediators and pathways of cell signaling, including p38/MAPK, Bax/Bcl2, Nrf2, TNF-α, p65/NF-κB, p53, ERK1/2, SAPK/JNK, caspases-3/-9, and ROS/NF-κB/COX-2 [47].
Some cancer types such as breast neoplasms [48] have been associated with inflammation [49]. Thus, females that may experience two inflammatory processes (e.g., obesity and breast cancer) have been followed in clinical trials to assess ginger’s anti-inflammatory effects compared to placebo [50]. Ginger was associated with a decrease in IL-10 compared to the placebo group, and other advantages, such as reductions in insulin, glucose, insulin resistance, LDL-C, and triglycerides. Some benefits were also measured, such as increases in HDL-C and HDL-C/LDL-C compared to the initial moment in the study. Therefore, ginger supplementation successfully modulated both inflammatory and metabolic indicators, suggesting mitigation of inflammation symptoms. Since these biomarkers are connected to the inception of breast neoplasms, ginger supplementation may, therefore, exert some protection against cancer. Furthermore, patients in the early stages of cancer may also benefit from ginger supplementation, especially those patients receiving a chemotherapy treatment that causes a highly inflammatory internal process [51][52].

This entry is adapted from the peer-reviewed paper 10.3390/molecules27217223

References

  1. Petrelli, F.; Mariani, F.M.; Alunno, A.; Puxeddu, I. Pathogenesis of rheumatoid arthritis: One year in review 2022. Clin. Exp. Rheumatol. 2022, 40, 475–482.
  2. Radu, A.-F.; Bungau, S.G. Management of rheumatoid arthritis: An overview. Cells 2021, 10, 2857.
  3. Bullock, J.; Rizvi, S.A.; Saleh, A.M.; Ahmed, S.S.; Do, D.P.; Ansari, R.A.; Ahmed, J. Rheumatoid arthritis: A brief overview of the treatment. Med. Princ. Pract. 2018, 27, 501–507.
  4. Da Fonseca, L.J.S.; Nunes-Souza, V.; Goulart, M.O.F.; Rabelo, L.A. Oxidative stress in rheumatoid arthritis: What the future might hold regarding novel biomarkers and add-on therapies. Oxid. Med. Cell Longev. 2019, 2019, 7536805.
  5. Scherer, H.U.; Häupl, T.; Burmester, G.R. The etiology of rheumatoid arthritis. J. Autoimmun. 2020, 110, 102400.
  6. Nelson, J.; Sjöblom, H.; Gjertsson, I.; Ulven, S.M.; Lindqvist, H.M.; Bärebring, L. Do Interventions with Diet or Dietary Supplements Reduce the Disease Activity Score in Rheumatoid Arthritis? A Systematic Review of Randomized Controlled Trials. Nutrients 2020, 12, 2991.
  7. Funk, J.L.; Frye, J.B.; Oyarzo, J.N.; Chen, J.; Zhang, H.; Timmermann, B.N. Anti-inflammatory effects of the essential oils of ginger (Zingiber officinale Roscoe) in experimental rheumatoid arthritis. PharmaNutrition 2016, 4, 123–131.
  8. Funk, J.L.; Frye, J.B.; Oyarzo, J.N.; Timmermann, B.N. Comparative effects of two gingerol-containing Zingiber officinale extracts on experimental rheumatoid arthritis. J. Nat. Prod. 2009, 72, 403–407.
  9. Bischoff-Kont, I.; Primke, T.; Niebergall, L.S.; Zech, T.; Fürst, R. Ginger Constituent 6-Shogaol Inhibits Inflammation- and Angiogenesis-Related Cell Functions in Primary Human Endothelial Cells. Front. Pharmacol. 2022, 13, 844767.
  10. Ilic, N.M.; Dey, M.; Poulev, A.A.; Logendra, S.; Kuhn, P.E.; Raskin, I. Anti-inflammatory activity of grains of paradise (Aframomum melegueta Schum) extract. J. Agric. Food Chem. 2014, 62, 10452–10457.
  11. Nonaka, K.; Bando, M.; Sakamoto, E.; Inagaki, Y.; Naruishi, K.; Yumoto, H.; Kido, J.-I. 6-Shogaol Inhibits Advanced Glycation End-Products-Induced IL-6 and ICAM-1 Expression by Regulating Oxidative Responses in Human Gingival Fibroblasts. Molecules 2019, 24, 3705.
  12. Yang, C.; Long, D.; Sung, J.; Alghoul, Z.; Merlin, D. Orally Administered Natural Lipid Nanoparticle-Loaded 6-Shogaol Shapes the Anti-Inflammatory Microbiota and Metabolome. Pharmaceutics 2021, 13, 1355.
  13. Bischoff-Kont, I.; Fürst, R. Benefits of Ginger and Its Constituent 6-Shogaol in Inhibiting Inflammatory Processes. Pharmaceuticals 2021, 14, 571.
  14. Bashir, N.; Ahmad, S.B.; Rehman, M.U.; Muzamil, S.; Bhat, R.R.; Mir, M.U.R.; Shazly, G.A.; Ibrahim, M.A.; Elossaily, G.M.; Sherif, A.Y.; et al. Zingerone (4-(four-hydroxy-3-methylphenyl) butane-two-1) modulates adjuvant-induced rheumatoid arthritis by regulating inflammatory cytokines and antioxidants. Redox Rep. 2021, 26, 62–70.
  15. Argüelles Martín, F.; Argüelles Arias, F. Enfermedad inflamatoria intestinal. Pediatr. Integr. 2003, 7, 115–124.
  16. Masoodi, I.; Alshanqeeti, A.S.; Ahmad, S.; Alyamani, E.J.; A Al-Lehibi, A.; Qutub, A.N.; Alsayari, K.N.; O Alomair, A. Microbial dysbiosis in inflammatory bowel diseases: Results of a metagenomic study in Saudi Arabia. Minerva Gastroenterol. Dietol. 2019, 65, 177–186.
  17. Guo, S.; Geng, W.; Chen, S.; Wang, L.; Rong, X.; Wang, S.; Wang, T.; Xiong, L.; Huang, J.; Pang, X.; et al. Ginger Alleviates DSS-Induced Ulcerative Colitis Severity by Improving the Diversity and Function of Gut Microbiota. Front. Pharmacol. 2021, 12, 632569.
  18. Marchesi, J.R.; Adams, D.H.; Fava, F.; Hermes, G.D.A.; Hirschfield, G.M.; Hold, G.; Quraishi, M.N.; Kinross, J.; Smidt, H.; Tuohy, K.M.; et al. The gut microbiota and host health: A new clinical frontier. Gut 2016, 65, 330–339.
  19. Lu, Y.; Li, X.; Liu, S.; Zhang, Y.; Zhang, D. Toll-like receptors and inflammatory bowel disease. Front. Immunol. 2018, 9, 72.
  20. Dejban, P.; Nikravangolsefid, N.; Chamanara, M.; Dehpour, A.; Rashidian, A. The role of medicinal products in the treatment of inflammatory bowel diseases (IBD) through inhibition of TLR4/NF-kappaB pathway. Phyther. Res. 2021, 35, 835–845.
  21. Pithadia, A.B.; Jain, S. Treatment of inflammatory bowel disease (IBD). Pharmacol. Rep. 2011, 63, 629–642.
  22. Kane, S. What physicians don’t know about patient dietary beliefs and behavior can make a difference. Expert Rev. Gastroenterol. Hepatol. 2012, 6, 545–547.
  23. Krajewski, D.; Polukort, S.H.; Gelzinis, J.; Rovatti, J.; Kaczenski, E.; Galinski, C.; Pantos, M.; Shah, N.N.; Schneider, S.S.; Kennedy, D.R.; et al. Protein Disulfide Isomerases Regulate IgE-Mediated Mast Cell Responses and Their Inhibition Confers Protective Effects During Food Allergy. Front. Immunol. 2020, 11, 606837.
  24. Navaneethan, U.; Lashner, B.A. Effects of Immunosuppression and Liver Transplantation on Inflammatory Bowel Disease in Patients With Primary Sclerosing Cholangitis. Clin. Gastroenterol. Hepatol. 2013, 11, 524–525.
  25. Nikkhah Bodagh, M.; Maleki, I.; Hekmatdoost, A. Ginger in gastrointestinal disorders: A systematic review of clinical trials. Food Sci. Nutr. 2019, 7, 96–108.
  26. Ajayi, B.O.; Adedara, I.A.; Farombi, E.O. Protective mechanisms of 6-gingerol in dextran sulfate sodium-induced chronic ulcerative colitis in mice. Hum. Exp. Toxicol. 2018, 37, 1054–1068.
  27. Zhang, M.; Xu, C.; Liu, D.; Han, M.K.; Wang, L.; Merlin, D. Oral delivery of nanoparticles loaded with ginger active compound, 6-shogaol, attenuates ulcerative colitis and promotes wound healing in a murine model of ulcerative colitis. J. Crohn’s Colitis 2018, 12, 217–229.
  28. Li, X.-H.; McGrath, K.C.-Y.; Nammi, S.; Heather, A.K.; Roufogalis, B.D. Attenuation of liver pro-inflammatory responses by Zingiber officinale via inhibition of NF-kappa B activation in high-fat diet-fed rats. Basic Clin. Pharmacol. Toxicol. 2012, 110, 238–244.
  29. Grzanna, R.; Lindmark, L.; Frondoza, C.G. Ginger—An herbal medicinal product with broad anti-inflammatory actions. J. Med. Food 2005, 8, 125–132.
  30. Lashgari, N.; Roudsari, N.M.; Khayatan, D.; Shayan, M.; Momtaz, S.; Roufogalis, B.D.; Abdolghaffari, A.H.; Sahebkar, A. Ginger and its constituents: Role in treatment of inflammatory bowel disease. BioFactors 2022, 48, 7–21.
  31. Van Tilburg, M.A.L.; Palsson, O.S.; Levy, R.L.; Feld, A.D.; Turner, M.J.; Drossman, D.A.; Whitehead, W.E. Complementary and alternative medicine use and cost in functional bowel disorders: A six month prospective study in a large HMO. BMC Complement Altern Med. 2008, 8, 46.
  32. Zhang, L.; Qing, P.; Yang, H.; Wu, Y.; Liu, Y.; Luo, Y. Gut Microbiome and Metabolites in Systemic Lupus Erythematosus: Link, Mechanisms and Intervention. Front Immunol. 2021, 12, 686501.
  33. Islam, M.A.; Khandker, S.S.; Kotyla, P.J.; Hassan, R. Immunomodulatory Effects of Diet and Nutrients in Systemic Lupus Erythematosus (SLE): A Systematic Review. Front. Immunol. 2020, 11, 1477.
  34. Allen, M.E.; Rus, V.; Szeto, G.L. Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies. Trends Mol. Med. 2021, 27, 152–171.
  35. Illescas-Montes, R.; Corona-Castro, C.C.; Melguizo-Rodríguez, L.; Ruiz, C.; Costela-Ruiz, V.J. Infectious processes and systemic lupus erythematosus. Immunology 2019, 158, 153–160.
  36. Chen, Y.; Lyga, J. Brain-skin connection: Stress, inflammation and skin aging. Inflamm. Allergy-Drug Targets 2014, 13, 177–190.
  37. Xu, F.; Xu, J.; Xiong, X.; Deng, Y. Salidroside inhibits MAPK, NF-κB, and STAT3 pathways in psoriasis-associated oxidative stress via SIRT1 activation. Redox Rep. 2019, 24, 70–74.
  38. Goldminz, A.M.; Au, S.C.; Kim, N.; Gottlieb, A.B.; Lizzul, P.F. NF-κB: An essential transcription factor in psoriasis. J. Dermatol. Sci. 2013, 69, 89–94.
  39. Nguyen, T.T.; Ung, T.T.; Li, S.; Lian, S.; Xia, Y.; Park, S.Y.; Do Jung, Y. Metformin inhibits lithocholic acid-induced interleukin 8 upregulation in colorectal cancer cells by suppressing ROS production and NF-kB activity. Sci. Rep. 2019, 9, 1–13.
  40. Hara-Chikuma, M.; Satooka, H.; Watanabe, S.; Honda, T.; Miyachi, Y.; Watanabe, T.; Verkman, A.S. Aquaporin-3-mediated hydrogen peroxide transport is required for NF-κB signalling in keratinocytes and development of psoriasis. Nat. Commun. 2015, 6, 1–4.
  41. Wang, J.; Ke, W.; Bao, R.; Hu, X.; Chen, F. Beneficial effects of ginger Zingiber officinale Roscoe on obesity and metabolic syndrome: A review. Ann. N. Y. Acad. Sci. 2017, 1398, 83–98.
  42. Raja, D.A. Immunology of Tuberculosis. Indian J. Med. Res. 2004, 120, 213–232.
  43. Javadi, B. Diet Therapy for Cancer Prevention and Treatment Based on Traditional Persian Medicine. Nutr. Cancer 2018, 70, 376–403.
  44. Coussens, L.M.; Werb, Z. Inflammation and cancer. Nature 2002, 420, 860–867.
  45. Habib, S.H.M.; Makpol, S.; Abdul Hamid, N.A.; Das, S.; Ngah, W.Z.W.; Yusof, Y.A.M. Ginger extract (Zingiber officinale) has anti-cancer and anti-inflammatory effects on ethionine-induced hepatoma rats. Clinics 2008, 63, 807–813.
  46. De Lima, R.M.T.; dos Reis, A.C.; de Menezes, A.-A.P.M.; de Oliveira Santos, J.V.; de Oliveira Filho, J.W.G.; de Oliveira Ferreira, J.R.; de Alencar, M.V.O.B.; da Mata, A.M.O.F.; Khan, I.N.; Islam, A.; et al. Protective and therapeutic potential of ginger (Zingiber officinale) extract and -gingerol in cancer: A comprehensive review. Phytother. Res. 2018, 32, 1885–1907.
  47. Wang, S.; Zhang, C.; Yang, G.; Yang, Y. Biological properties of 6-gingerol: A brief review. Nat. Prod. Commun. 2014, 9, 1027–1030.
  48. Agnoli, C.; Grioni, S.; Sieri, S.; Sacerdote, C.; Ricceri, F.; Tumino, R.; Frasca, G.; Pala, V.; Mattiello, A.; Chiodini, P.; et al. Metabolic syndrome and breast cancer risk: A case-cohort study nested in a multicentre italian cohort. PLoS ONE 2015, 10, e0128891.
  49. Berrino, F.; Villarini, A.; Traina, A.; Bonanni, B.; Panico, S.; Mano, M.P.; Mercandino, A.; Galasso, R.; Barbero, M.; Simeoni, M.; et al. Metabolic syndrome and breast cancer prognosis. Breast Cancer Res. Treat. 2014, 147, 159–165.
  50. Karimi, N.; Roshan, V.D.; Bayatiyani, Z.F. Individually and combined water-based exercise with ginger supplement, on systemic inflammation and metabolic syndrome indices, among the obese women with breast neoplasms. Iran. J. Cancer Prev. 2015, 8, e3856.
  51. Conklin, K.A. Chemotherapy-associated oxidative stress: Impact on chemotherapeutic effectiveness. Integr. Cancer Ther. 2004, 3, 294–300.
  52. Danwilai, K.; Konmun, J.; Sripanidkulchai, B.-O.; Subongkot, S. Antioxidant activity of ginger extract as a daily supplement in cancer patients receiving adjuvant chemotherapy: A pilot study. Cancer Manag. Res. 2017, 9, 11–18.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback